Clinical Trial

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract cancer after the failure of at least two prior systemic therapies.
Trial Details
NCT Number NCT07704177
Lead Sponsor Peking Union Medical College Hospital
Conditions Biliary Tract Neoplasms Immunotherapy
Enrollment 70 participants
Start Date 2026-04-15
Primary Completion 2027-04-15 (estimated)
Study Completion 2028-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-15